newsfilter
← Latest News
Business Wire·

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Full-year revenue increased 10% to $727 million; Full-year clinical revenue grew 15%, or 13% excluding the Pathline acquisition; Successfully resolved RaDaR ST patent litigation NeoGenomics, Inc. (NASDAQ:NEO) (the